Don't wanna be here? Send us removal request.
Statistics
We looked inside some of the posts by yes-shashi-blog and here's what we found interesting.
Average Info
Notes Per Post
2
Likes Per Post
1
Reblog Per Post
1
Reply Per Post
0
Time Between Posts
4 days
Number of Posts By Type
Link
6
Text
9
Last Seen Tumblr Blogs
Fun Fact
69% of Tumblr users are millennials.
Link
The Cardiac Stents Market was valued at US $10.01 billion in the year 2018 and is estimated to reach US $15.54 billion by 2026, at a CAGR of 5.65%
0 notes
Text
Supportive Sports Insoles Market to Register Substantial Expansion by 2026
The Sports Insoles Market was valued at US$181.76 million in the year 2018 and is estimated to reach US$380.77 million by 2026, at a CAGR of 9.39%.
Sports insoles are specially designed to enhance comfort for athletes and sportsperson. Sports insoles minimize pain, increase performance, prevent injury, support the arch, improves posture and balance with neutral alignment. Sports insoles are customized by perfect distribution of the pressure zones, propulsion layer cushioning for easy toe movements and extra comfort, shock absorption system to reduce the risk of injury, stabilizing the rear and mid foot to optimize pronation/supination throughout the foot's movement and maintenance of multidirectional motions. Manufacturing of sports insoles is associated with advanced technologies, 3D printing. Recent advancements included customization of insoles with foot print, sensory balance & control options and environment friendly products.
Increasing focus on participation in sports across geographies and injury prevention and injury management, more investment by government on sports and increase in franchise-based sports events are expected to drive the market growth throughout the forecast period. However, challenges such as diagnosis of the scenario for which the insoles are required, lack of expertise for understanding the customer’s requirements, largely unaddressed population in emerging markets and designing flaws that largely affects the output should be addressed for further growth among the geographies wherein more focus on the emerging markets should also be taken care.
North American region dominated the market share with more than 55% of the contribution towards the revenue growth with US alone contributing more than 50% of the global market share. This can be attributed to Presence of major market players & advancements and more participation is always expected in the region with involvement from the young age itself. The European region contributes more than 25% of the market share. However, Asia Pacific & LAMEA region together contributes less than 10% of the global market share. But with more focus on sports in the Asia Pacific region, especially China and India are the major hotspots owing to govt. policies, increasing focus on sports, plans for reducing the injury and better injury management. Sports insoles dominated the market with more than 45%, followed by skiing and running segments that contributes together for more than 75%. The sports segment for adult is more than 70% and children segment contributing more than 25% to the market share.
Request for Sample Pages @ https://www.optimainsights.org/sample-request/172-sports-insoles-market
Optima Insights provides the latest update on the industry trends, products & pipeline analysis with country, regional and global revenue forecast till the year 2026. The Sports Insoles market is segmented based on Product (Customized & Pre-fabricated); Material (Gel, Ethyl-vinyl acetate, Composite Carbon fibers, Cork, Leather, Polyethylene Foams, Thermoplastic & others); User Age (Pediatric, Adult); Distribution Channel (Online stores, Hospitality & Specialty clinics, drug stores) and Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa).
The report profiles more than 20 companies with more than 100 products with production technology, materials, indications and features. Major companies contributing to the Sports Insoles include Dr. Scholls, Foot Science International, SIDAS, Superfeet Worldwide Inc, Acor Orthopaedic, Inc, Celtic orthotics, Aetrex Worldwide, Inc., Acor Orthopaedic, Inc and many more…
Research Scope
· Provides a detailed Analysis of the Market Structure along with forecast of the various segments and sub-segments.
· Provides a Comparative Analysis of Key Marketed and Pipeline Products.
· Provides Key Information on Players involved.
· Provides a Complete Overview of Market Segments and the Regional Outlook.
· Provides In-depth Coverage of Key News, including Major Mergers, Acquisitions and Product Development updates such as clinical trial progression updates and regulatory updates.
The Report Provides Key Insights on
· History of the Sports Insoles Market, 2015 to 2017
· Forecast of the Sports Insoles Market Growth till the year 2026
· The key market drivers, restraints, challenges, future opportunities and the market dynamics driving the Sports Insoles Market
· Analysis of potential growth segments which will drive the market
· Landscape analysis of the major companies, and new market entrants and companies which possess disruptive technologies which can change the trend of the entire market
· Key market approaches adopted by the organizations and in-depth intelligence of potential strategies which could alter the market dynamics
Request for TOC @ https://www.optimainsights.org/request-toc/172-sports-insoles-market
About Us
Optima Insights is an innovative research and insights-driven enterprise committed to offering actionable intelligence to the global life science and healthcare market. We believe that meaningful insights and improved strategic content hold the key to improved ROI for our clients. We strike an innovative engagement model with our clients to Co-Create Intelligence that would address very specific issues facing them within their functional areas. We continuously support clients through the entire journey map to enable them to make better business decisions towards attaining market leadership.
Contact
Optima Insights
Mr Chucks G
+91 966 6620 365 (Asia) | +1 424 2554 365 (US)
Email: [email protected]
https://www.optimainsights.org
0 notes
Text
Inhalable Drug Delivery Devices Market expected to Reach US$41.96 billion at a CAGR of 4.1%
The Inhalable Drug Delivery Devices Market was valued at US$30.43 billion in the year 2018 and is estimated to reach US$41.96 billion by 2026, at a CAGR of 4.1%.
Inhalation route is one of the effective and quicker way of drug administration directly to the lungs, for treating acute and chronic pulmonary disorders such as chronic obstructive pulmonary disorder, asthma, etc. Besides, recent research also suggests that pulmonary route could be an effective way of drug delivery to the systemic circulation. This accompanies with advantages with ease of use, quicker onset of action and entry into metabolic cycle. The inhalation drug delivery systems include technologies such as dry powder inhalers, pressurized metered inhalers, nebulizers, etc. and have several advantages over the conventional oral and intravenous drug delivery methods.
However, while designing the drugs that can be used through inhalation there are certain challenges such as generating drug particles of suitable size range, aggregation of particles in humid conditions, recrystallisation during shelf storage and irregular particle surface due to which the efficacy of the treatment might decrease will in turn could deter the market growth. With an increase in the number of individuals suffering from respiratory disorders augmenting year-on-year, the market for inhalable drug delivery devices is expected to achieve a considerable growth during the forecast period. Also, inhalation route-based drug delivery systems for diseases like cystic fibrosis, neurological disorders, pain management, etc. are underway. This is attributed to the success of the inhalation insulin device Exubera®. Thus, the utility for inhalable drug delivery devices has diversified over years and is expected to reflect in the market dynamics. Increase in the health awareness, increasing health problems, air pollution is expected to contribute to the market growth during the forecast period.
According to World Health Organization (WHO), the burden of Asthma among countries like Australia, Sweden, UK, Netherlands, India and Brazil collectively account for more than 20% of patient population. While the COPD burden is prevalent among low- and middle- income countries where air pollution is considerably high. Especially, in regions such as India and China, where tobacco chewing, cigarette smoking and pollution to highest levels. The EU5 countries along contributed more than 30% of the market share in 2018 and is expected to hold similar contribution throughout the forecast period.
Optima Insights provides the latest update on the industry trends, products & pipeline analysis with country, regional and global revenue forecast till the year 2026. The analysis of the market is segmented into product (pressurized metered-dose inhalers, nebulizers market, dry powder inhalers, thermal vaporization aerosol, others); technology (manual, digital); application (respiratory, non-respiratory); end user (hospital and clinics, ambulatory care, home care); region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)
Request for Sample Pages @ https://www.optimainsights.org/sample-request/202-inhalable-drug-delivery-devices-market
Major companies contributing to the Inhalable Drug Delivery Devices include 3M, AstraZeneca, Propeller health; Omron Corporation; Pfizer; Roche; Boehringer Ingelheim, GlaxoSmithKline, Merck & Co, Novartis, Sunovion Pharmaceuticals, Teva Pharmaceuticals, Envigo and many more…
Research Scope
· Provides a detailed Analysis of the Market Structure along with forecast of the various segments and sub-segments.
· Provides a Comparative Analysis of Key Marketed and Pipeline Products.
· Provides Key Information on Players involved.
· Provides a Complete Overview of Market Segments and the Regional Outlook.
· Provides In-depth Coverage of Key News, including Major Mergers, Acquisitions and Product Development updates such as clinical trial progression updates and regulatory updates.
The Report Provides Key Insights on
· History of the Inhalable Drug Delivery Devices Market, 2015 to 2017
· Forecast of the Inhalable Drug Delivery Devices Market Growth till the year 2026
· The key market drivers, restraints, challenges, future opportunities and the market dynamics driving the Inhalable Drug Delivery Devices Market
· Analysis of potential growth segments which will drive the market
· Landscape analysis of the major companies, and new market entrants and companies which possess disruptive technologies which can change the trend of the entire market
· Key market approaches adopted by the organizations and in-depth intelligence of potential strategies which could alter the market dynamics
· Download Complete TOC of the Report @ https://www.optimainsights.org/request-toc/202-inhalable-drug-delivery-devices-market
About Us
Optima Insights is an innovative research and insights-driven enterprise committed to offering actionable intelligence to the global life science and healthcare market. We believe that meaningful insights and improved strategic content hold the key to improved ROI for our clients. We strike an innovative engagement model with our clients to Co-Create Intelligence that would address very specific issues facing them within their functional areas. We continuously support clients through the entire journey map to enable them to make better business decisions towards attaining market leadership.
Contact
Optima Insights
Mr Chucks G
+91 966 6620 365 (Asia) | +1 424 2554 365 (US)
Email: [email protected]
https://www.optimainsights.org
0 notes
Link
The Bone Fixation Devices Market was valued at US $7.68 billion in the year 2018 and is estimated to reach US $13.11 billion by 2027, at a CAGR of 6.12%.
0 notes
Text
Global Bone Fixation Plates Market Share, Growth, Size, Trends and Forecast 2018 - 2027
The Bone Fixation Devices Market was valued at US $7.68 billion in the year 2018 and is estimated to reach US $13.11 billion by 2027, at a CAGR of 6.12%.
Bone Fixation Devices are used to maintain the stability of the fractured bones through immobilization and offering proper alignment during the healing process. There are two types of bone fixation devices, external and internal. Internal Fixation devices include screws (cortical, cancellous), plates (straight, complex compression), pins and rods. Among these, the plates are expected to hold the bones together and the screws help in fixation of the bones to the implants. External fixation devices are used for temporary treatment of fractures, mostly in conditions associated with multiple injuries, where complex surgery to fix the fracture is not possible.
The major market drivers include a continuous growing orthopedic market, an increase in public awareness, R&D, rising healthcare infrastructure, increasing cases of accidents, high prevalence of osteoporosis and osteoporotic fractures.
In recent times, there is an increase in age-specific incidence rates of fractures among them women are more vulnerable. Further, increasing the geriatric population associated with fragility fractures also triggers the demand for bone fixation devices market. International Osteoporosis Foundation estimated over 200 million people to be suffering from osteoporosis worldwide. Among them, women over 50 years of age will experience osteoporotic fractures which include at least 40% of menopausal women; while 15-30% of men will sustain one or more fragility fractures in their lifetime.
The key market restraints for bone fixation devices market are stringent regulations of manufacturing, high cost of bone fracture surgeries, high cost, and risks associated with bone fixation screws such as loss of function and muscular morbidity, bone infection, and loosening of screws. The major challenges to be met for bone fixation devices market are the usage of more novel materials, to develop advanced bone fixation procedures and to develop the low risk of infection internal fixation devices. Internal fixation device accounts major share of more than 70% when compared with external fixation devices in bone fixation market. Focusing more on the development and marketing of bioabsorbable fixators might boost the bone fixation market growth.
Major companies for Bone Fixation Devices market include Medtronic, Zimmer Biomet, Atlantic Surgical, Orthofix, BoneSupport AB, Osteomed, Depuy Synthes, Stryker. According to clinicaltrials.gov, there are more than 300 active clinical trials for bone fixation devices.
Recent Updates
· In September 2019, Flower Orthopedics introduced a new low-profile syndesmotic fixation device, the FlowerRope
· FDA issued clearance OrthoSpin’s robot-assisted external fixation device
· MedShape, Inc. has announced the commercial launch of its DynaClip™ Bone Fixation System
Bone Fixation Devices Market Based on Product type (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn):
· Internal Fixation Devices
· External Fixation Devices
Bone Fixation Devices Market Based on Geographic Region (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)
· North America
· Europe
· APAC
· LAMEA
Research Scope
· Provides a detailed Analysis of the Market Structure along with forecast of the various segments and sub-segments.
· Provides a Comparative Analysis of Key Marketed and Pipeline Products.
· Provides Key Information on Players involved.
· Provides a Complete Overview of Market Segments and the Regional Outlook.
· Provides In-depth Coverage of Key News, including Major Mergers, Acquisitions and Product Development updates such as clinical trial progression updates and regulatory updates.
The Report Provides Key Insights on
· History of the Bone Fixation Devices Market, 2015 to 2018
· Forecast of the Bone Fixation Devices Market Growth till the year 2027
· The key market drivers, restraints, challenges, future opportunities and the market dynamics driving the Bone Fixation Devices Market
· Analysis of potential growth segments which will drive the market
· Landscape analysis of the major companies, and new market entrants and companies which possess disruptive technologies which can change the trend of the entire market
· Key market approaches adopted by the organizations and in-depth intelligence of potential strategies which could alter the market dynamics
About Us
Optima Insights is an innovative research and insights-driven enterprise committed to offering actionable intelligence to the global life science and healthcare market. We believe that meaningful insights and improved strategic content hold the key to improved ROI for our clients. We strike an innovative engagement model with our clients to Co-Create Intelligence that would address very specific issues facing them within their functional areas. We continuously support clients through the entire journey map to enable them to make better business decisions towards attaining market leadership.
Contact
Optima Insights
Mr Chucks G
+91 966 6620 365 (Asia) | +1 424 2554 365 (US)
Email: [email protected]
https://www.optimainsights.org
0 notes
Link
The Hemostasis and Tissue Sealants Market was valued at US $2.12 billion in the year 2018 and is estimated to reach US $4.29 billion by 2026, at a CAGR of 9.21%.
0 notes
Text
Tissue Sealants Market | Key Trends and Opportunity Analysis 2026
The Hemostasis and Tissue Sealants Market was valued at US $2.12 billion in the year 2018 and is estimated to reach US $4.29 billion by 2026, at a CAGR of 9.21%.
Tissue sealants are glue-like substances used to bind the tissue after a surgical procedure or after an injury to prevent excessive blood loss. Hemostasis is the principal clotting mechanism. Nevertheless, in case of major injuries or trauma, tissue sealants characteristically help in sealing the wounds aiding hemostasis to stop blood loss. Tissue sealants have long contributed to minimizing blood loss, surgical duration, flexibility, quicker healing, minimal rejection rate and also useful in anticoagulated patients. In recent times, the number of sports injuries, cardiac surgeries, trauma cases, etc. have upsurged and are contributing to the growth of the tissue sealants market. According to the world health organization (WHO), the mortality rate attributed to accidents is about 1.24 million, every year while individuals sustaining non-fatal injuries account for around 30-50 million. Thus, a demand for blood loss management is on the rise. Besides, increasing injury-prone geriatric and diabetic populations are also considered as major market drivers to the tissue sealants market.
Fibrin sealants consisting of a combination of fibrinogen and thrombin component are known to form cross-linkages to coagulate the blood arresting the blood loss within five minutes in more than 90% of the cases. These fibrin sealants are mostly used in cardiovascular surgeries and it is expected that more than 450000 cardiovascular surgeries will be carried out in the US alone by the year 2021. Thus, the fibrin sealant segment is expected to dominate the tissue sealant market for at least 3-4 years during the forecast period and its application in cardiovascular surgeries is expected to lead the market share.
North American region consisting of excellent healthcare infrastructure, exposure to various advanced technologies, access to healthcare, govt. policies etc. is expected to contribute primarily to the growth of the market during the forecast period. The Asia Pacific with an emancipating growth in the population, injuries, eye, cardiovascular and other major surgical cases are expected to witness lucrative growth during the forecast period. Especially, India and China, witnessing rapid transformation in the healthcare infrastructure and policies are anticipated to contribute to the market growth. Latin America due to the cost-effect surgical procedure is gaining limelight and is also boosting the tissue sealants market. Nonetheless, the rising cost of tissue sealant products had decreased the affordability ratio and reimbursement policies in Asia Pacific and Latin American countries is creating a challenge for the tissue sealants market.
In the present study, we have segmented the market by Products (Natural/Biological Sealants and Adhesives and Synthetic and Semi-synthetic Sealants and Adhesives), Indication (Surgical hemostasis, Tissue Sealing and Tissue Engineering), Application (General surgery, CNS surgery, cardiothoracic surgery, orthopedic surgery, cosmetic surgery, urological surgery, pulmonary surgery, ophthalmic surgery, others) and by Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa)
Major companies focused in this report are Baxter International, Braun Melsungen AG, CryoLife, Medtronic, Cohesion Technologies, C. R. Bard, Genzyme Corporation, Integra LifeSciences Corporation, Vivostat A/S, Sealantis, Ltd and Johnson & Johnson, Stryker Corporation, Smith & Nephew plc and many more…
Research Scope
· Provides a detailed Analysis of the Market Structure along with forecast of the various segments and sub-segments.
· Provides a Comparative Analysis of Key Marketed and Pipeline Products.
· Provides Key Information on Players involved.
· Provides a Complete Overview of Market Segments and the Regional Outlook.
· Provides In-depth Coverage of Key News, including Major Mergers, Acquisitions and Product Development updates such as clinical trial progression updates and regulatory updates.
The Report Provides Key Insights on
· History of the Hemostasis and Tissue Sealants Market, 2015 to 2017
· Forecast of the Hemostasis and Tissue Sealants Market till the year 2026
· The key market drivers, restraints, challenges, future opportunities and the market dynamics driving the Hemostasis and Tissue Sealants Market
· Analysis of potential growth segments which will drive the market
· Landscape analysis of the major companies, and new market entrants and companies which possess disruptive technologies which can change the trend of the entire market
· Key market approaches adopted by the organizations and in-depth intelligence of potential strategies which could alter the market dynamics
About Us
Optima Insights is an innovative research and insights-driven enterprise committed to offering actionable intelligence to the global life science and healthcare market. We believe that meaningful insights and improved strategic content hold the key to improved ROI for our clients. We strike an innovative engagement model with our clients to Co-Create Intelligence that would address very specific issues facing them within their functional areas. We continuously support clients through the entire journey map to enable them to make better business decisions towards attaining market leadership.
Contact
Optima Insights
Mr Chucks G
+91 966 6620 365 (Asia) | +1 424 2554 365 (US)
Email: [email protected]
https://www.optimainsights.org
0 notes
Link
The Medical Gases and Equipment Market was valued at US $ 8.6 billion in the year 2018 and is estimated to reach US $ 16.67 billion by 2026, at a CAGR of 8.62%.
0 notes
Text
Global Medical Gases and Equipment Market Trends & Forecast by 2018-2026
The Medical Gases and Equipment Market was valued at US $ 8.6 billion in the year 2018 and is estimated to reach US $ 16.67 billion by 2026, at a CAGR of 8.62%.
Medical gases and equipment are used in hospitals during surgeries and ventilatory, operating rooms, intensive care unit (ICU) & emergency services. They are primarily used during the treatment of chronic respiratory disorders, laser surgery, sleep apnea, cryosurgery, and dental surgeries. Besides medical gases are used in several therapeutic, diagnostic, pharmaceutical manufacturing & research facilities. Licensing and marketing authorization from Regulatory Authorities is required to manufacture and distribute the medical gases.
According to WHO, the global presence of chronic respiratory conditions is 20.8% in rural and 19.4% in the urban areas. An increase in the prevalence of respiratory conditions increases the demand for medical gas and equipment supply. There is a medical gas supply set up in most of the hospitals and healthcare facilities around the world, with different regulation policies and color-coding policies of gas pipes. There is an increase in the number of hospitals and health care facilities due to awareness and urbanization. Registration of newer health facilities is progressing rapidly, approximately 19,217 as estimated by WHO in 2017 worldwide. This might boost the medical gas and equipment supply-demand in the forecast period.
The key market drivers for medical gases and equipment include an increase in the use of medical gases in surgeries, growing geriatric population, an increase in the prevalence of respiratory disorders especially asthma & COPD, increasing hospitalization, emergency visits, surgeries, anesthesia, and ventilated cases.
The major market restraints are purity check of gases as impurities present in gases lead to infections, stringent regulatory process guidelines, and licensing approvals, inspecting medical gas supply units periodically and complexity of medical gas production, storage, and delivery. The major challenges are the modernization of medical gas standards and the means of supply in hospital & health-care facilities. Highly developing healthcare systems and investments in the development of patented technologies in medical gases and equipment will impact the market growth positively ion forecast period.
Major companies for Medical Gases and Equipment market include The Linde Group, Praxair Technology Inc, Atlas Copco, Amico Corporation, Air Products and Chemicals Inc. and Taiyo Nippon Sanso Corporation.
Recent Updates
· CAIRE, a Georgia-based oxygen supply manufacturer, has launched a new FreeStyle® Comfort® portable oxygen concentrator equipped with autoSAT® technology
· Kitajima Sanso, medical gas distributor builds medical oxygen filling plant in Myanmar
· Linde AG has agreed to sell its South India business to Japan’s Air Water Inc. (AWI) as part of a deal to complete its global merger with US-based Praxair Inc
· Recently, Cavagna Group designed the Viproxy NEOS, a new digital medical valve integrated with pressure regulator (VIPR)
Medical Gases and Equipment Market Based on Product Type (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn): Medical Gases
· Nitrogen
· Nitrous Oxide
· Oxygen
· Carbon dioxide
· Helium
· Medical Air
Medical Gas Mixtures
· Lung Diffusion
· Blood Gas
· Sterilant Gas
· Medical Drug Gas
· Breathing Zone Monitoring
Medical Gas Equipment
· Air Compressors
· Vacuum systems
· Flow Systems
· Cylinders
· Alarm Systems
· Masks
Medical Gases and Equipment Market Based on Application Type (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn):
· Therapeutic
· Diagnostic
· Pharmaceutical manufacturing & Research
Medical Gases and Equipment Market Based on Geographic Region (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)
· North America
· EuropeAPAC
· LAMEA
Research Scope
· Provides a detailed Analysis of the Market Structure along with forecast of the various segments and sub-segments.
· Provides a Comparative Analysis of Key Marketed and Pipeline Products.
· Provides Key Information on Players involved.
· Provides a Complete Overview of Market Segments and the Regional Outlook.
· Provides In-depth Coverage of Key News, including Major Mergers, Acquisitions and Product Development updates such as clinical trial progression updates and regulatory updates.
The Report Provides Key Insights on
· History of the Medical Gases and Equipment Market, 2015 to 2017
· Forecast of the Medical Gases and Equipment Market Growth till the year 2026
· The key market drivers, restraints, challenges, future opportunities and the market dynamics driving the Medical Gases and Equipment Market
· Analysis of potential growth segments which will drive the market
· Landscape analysis of the major companies, and new market entrants and companies which possess disruptive technologies which can change the trend of the entire market
· Key market approaches adopted by the organizations and in-depth intelligence of potential strategies which could alter the market dynamics
About Us
Optima Insights is an innovative research and insights-driven enterprise committed to offering actionable intelligence to the global life science and healthcare market. We believe that meaningful insights and improved strategic content hold the key to improved ROI for our clients. We strike an innovative engagement model with our clients to Co-Create Intelligence that would address very specific issues facing them within their functional areas. We continuously support clients through the entire journey map to enable them to make better business decisions towards attaining market leadership.
Contact
Optima Insights
Mr Chucks G
+91 966 6620 365 (Asia) | +1 424 2554 365 (US)
Email: [email protected]
https://www.optimainsights.org
0 notes
Link
The Sinusitis Treatment Market was valued at US $1.9 billion in the year 2018 and is estimated to reach US $3.7 billion by 2026, at a CAGR of 8.68%.
0 notes
Text
World Drugs for Sinusitis Market Analysis by top key players for Sinusitis Treatment Market
The Sinusitis Treatment Market was valued at US $1.9 billion in the year 2018 and is estimated to reach US $3.7 billion by 2026, at a CAGR of 8.68%.
Sinusitis results from inflammation of sinus lining, air cavities within passage of nose usually caused by infection (bacteria, and viruses), chemical, allergies, and autoimmune problems. Symptoms include nasal obstruction, Rhinorrhea (drainage and postnasal drip), loss of sense, smell & taste, discolored nasal discharge and facial pain pressure. Depending on severity, sinusitis is distinguished into acute, sub-acute and chronic, recurrent sinusitis.
According to Centers for Disease Control and Prevention (CDC), approximately 26.9 million people were diagnosed with sinusitis in the U.S (2018), which equals more than 12% of total population, of which viral sinus infections alone affects 9 out of 10 cases in adults and 5-7 out of 10 cases in children. In the United Kingdom, acute sinusitis affects 3 in 1000 while chronic sinusitis affects 1 in 1000. Generally, around 0.5% of all upper respiratory tract infections lead to sinusitis and around 15 to 40 episodes of acute sinusitis is observed per 1000 patients every year globally.
The major market driver for sinusitis treatment market is the rising incidence rate of sinusitis and prevalence of associated infections. Besides, advancement in R&D activities for newer drug development might impact global sinusitis treatment market positively. The market restraint is improper diagnosis and awareness of sinusitis. The major challenge for sinusitis treatment market include advancements in diagnostic procedures, developing new drugs as antibiotic resistance is observed in sinus infections and development of drugs to improve quality of life. Leading markets are observed in North America and European Regions due to high prevalence. Rising cases of sinusitis are also seen in Asian Pacific Regions and this is expected to increase the market growth in that region in forecast period.
The class of drugs used for the treatment of Sinusitis are antihistamines, corticosteroids, decongestants, NSAIDS, antibiotics, allergen immunotherapy, etc. For severe sinusitis, treatment involves surgical procedures (functional endoscopic sinus surgery (FESS), image guided surgery, Caldwell Luc operation).
Major companies for the treatment of Sinusitis Treatment include Bayer AG, Eli Lilly and Company, Bristol-Myers Squibb, Merck & Co Inc., Abbott Laboratories, Sanofi, AstraZeneca Plc, Novartis AG, Zydus Cadila, Beximco Pharmaceuticals Ltd, Janssen Pharmaceuticals, Pfizer Inc, Dr. Reddy’s Laboratories and Teva Pharmaceuticals. According to clinicaltrials.gov, there are around 49 active interventional trials for the treatment of Sinusitis.
Recent Updates
· Regeneron Pharmaceuticals and Sanofi Genzyme developed Dupixent (dupilumab) for treatment of chronic sinusitis
· Trivedi global, Inc. and Rudina Thanasi announced research results on a biofield energy treated nutraceutical for reducing inflammation and autoimmune disorders
Sinusitis Treatment Market Based on Treatment Class (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn):
· Antihistamines
· Corticosteroids
· Decongestants
· Allergen Immunotherapy
· Expectorants
· Antibiotics
· NSAIDS
Sinusitis Treatment Market Based on Geographic Region (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)
· North America
· Europe
· APAC
· LAMEA
Research Scope
· Provides a detailed Analysis of the Market Structure along with forecast of the various segments and sub-segments.
· Provides a Comparative Analysis of Key Marketed and Pipeline Products.
· Provides Key Information on Players involved.
· Provides a Complete Overview of Market Segments and the Regional Outlook.
· Provides In-depth Coverage of Key News, including Major Mergers, Acquisitions and Product Development updates such as clinical trial progression updates and regulatory updates.
The Report Provides Key Insights on
· History of the Sinusitis Treatment Market, 2015 to 2017
· Forecast of the Sinusitis Treatment Market Growth till the year 2026
· The key market drivers, restraints, challenges, future opportunities and the market dynamics driving the Sinusitis Treatment Market
· Analysis of potential growth segments which will drive the market
· Landscape analysis of the major companies, and new market entrants and companies which possess disruptive technologies which can change the trend of the entire market
· Key market approaches adopted by the organizations and in-depth intelligence of potential strategies which could alter the market dynamics
About Us
Optima Insights is an innovative research and insights-driven enterprise committed to offering actionable intelligence to the global life science and healthcare market. We believe that meaningful insights and improved strategic content hold the key to improved ROI for our clients. We strike an innovative engagement model with our clients to Co-Create Intelligence that would address very specific issues facing them within their functional areas. We continuously support clients through the entire journey map to enable them to make better business decisions towards attaining market leadership.
Contact
Optima Insights
Mr Chucks G
+91 966 6620 365 (Asia) | +1 424 2554 365 (US)
Email: [email protected]
https://www.optimainsights.org
0 notes
Text
Uterine Fibroids Treatment Market: Trends, Opportunities and Forecasts 2026
The Uterine Fibroids Treatment Market was valued at US $1.08 billion in the year 2018 and is expected to reach US $1.37 billion by 2026, with a CAGR of 2.97%.
Uterine Fibroids also called as uterine leiomyomas are benign tumors that develop from smooth muscle cells or fibrous connective tissue in the uterus. Symptoms of Uterine fibroids include heavy or prolonged periods, bleeding in between periods, pelvic pain and frequent urination. Complications associated with uterine fibroids are difficulty in getting pregnant, infertility, etc. Uterine fibroids can be categorized into intramural, submucosal and sub serosal types based on their location.
Approximately, 70-80% of women develop fibroids in their lifetime which is either asymptomatic or undiagnosed, of which around 40% of women are between of 30-55 years of age. Approximately 20 million women in North America, 24 Million women in Europe and over 70 million women in other regions such as Asia Pacific, Latin America, Middle East and Africa are affected by uterine fibroids. According to National Women’s Health Network, women aging in their 30-40’s are three times more vulnerable of developing fibroids. Majority of women with uterine fibroids remain asymptomatic and often are undiagnosed. Also, obese women with higher BMI’s particularly with excess abdominal fat are 2-3 more times more susceptible in developing uterine fibroids.
Treatment for uterine fibroids include hormonal, non-hormonal and surgical methods. Hormonal treatment includes Oral Contraceptives, Progestins/Antiprogestins, Gonadotropin Release Hormone (GnRH) Antagonists and Nonsteroidal anti-inflammatory drugs (NSAIDs) under Non-hormonal treatment. Surgical methods for the treatment of uterine fibroids include uterine artery embolization, myomectomy and hysterectomy. First line of treatment includes medical therapy to shrink fibroids and over the counter medications to control pain & bleeding while surgical methods are useful in latter stages of uterine fibroids development.
The major market driver for uterine fibroids treatment market include rise in prevalence of hormonal imbalance leading to fibroids and increase in female geriatric population. The market restraint for uterine fibroid treatment include high cost of treatment and alternative surgical treatment options other than therapeutics. The main challenge was to develop minimally invasive cost effective technologically advanced treatment for Uterine Fibroids and creating awareness on benefits of lifestyle modifications. Leading market trends were observed in U.S.A, European and African regions as ultrasound evidence shows that more than 80% of African American women and approximately 70% of white women have uterine fibroids by the age of 50. Due to rising prevalence of hormonal disorders and increased geriatric women population emerging market trends are observed in Asian Pacific regions with countries like India and China being the hotspots.
Major companies that develop therapeutic modalities for Uterine Fibroids Treatment include Allergan, Gedeon Richter, Repros Therapeutics, Bayer HealthCare, AbbVie, Myovant Sciences, ObsEva, GlaxoSmithKline Pharmaceuticals Limited, Pfizer Inc., Johnson & Johnson, Novartis AG, Eli Lilly and Company. According to clinicaltrials.gov, there are around 56 active interventional trials for Uterine Fibroids Treatment at present.
Recent Updates
· In August 2019, AbbVie, in cooperation with Neurocrine Biosciences announced the submission of a New Drug Application (NDA) for elagolix for the management of heavy menstrual bleeding (HMB) associated with uterine fibroids in women.
· Myovant Sciences is developing GnRH receptor antagonist relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids.
· Linzagolix is under development in Phase III for the treatment of Uterine Fibroids by OBSEVA in license with Kissei Pharmaceutical Co Ltd.
Uterine Fibroids Treatment Market Based on Treatment Class (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn): Hormonal treatment
· Oral Contraceptives
· Progestins/Antiprogestins
· Gonadotropin Release Hormone (GnRH) Antagonists
Non-hormonal treatment
· Nonsteroidal anti-inflammatory drugs (NSAIDs)
Uterine Fibroids Treatment Market Based on Geographic Region (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)
· North America
· Europe
· APAC
· LAMEA
Research Scope
· Provides a detailed Analysis of the Market Structure along with forecast of the various segments and sub-segments.
· Provides a Comparative Analysis of Key Marketed and Pipeline Products.
· Provides Key Information on Players involved.
· Provides a Complete Overview of Market Segments and the Regional Outlook.
· Provides In-depth Coverage of Key News, including Major Mergers, Acquisitions and Product Development updates such as clinical trial progression updates and regulatory updates.
The Report Provides Key Insights on
· History of the Uterine Fibroids Treatment Market, 2015 to 2017
· Forecast of the Uterine Fibroids Treatment Market Growth till the year 2026
· The key market drivers, restraints, challenges, future opportunities and the market dynamics driving the Uterine Fibroids Treatment Market
· Analysis of potential growth segments which will drive the market
· Landscape analysis of the major companies, and new market entrants and companies which possess disruptive technologies which can change the trend of the entire market
· Key market approaches adopted by the organizations and in-depth intelligence of potential strategies which could alter the market dynamics
About Us
Optima Insights is an innovative research and insights-driven enterprise committed to offering actionable intelligence to the global life science and healthcare market. We believe that meaningful insights and improved strategic content hold the key to improved ROI for our clients. We strike an innovative engagement model with our clients to Co-Create Intelligence that would address very specific issues facing them within their functional areas. We continuously support clients through the entire journey map to enable them to make better business decisions towards attaining market leadership.
Contact
Optima Insights
Mr Chucks G
+91 966 6620 365 (Asia) | +1 424 2554 365 (US)
Email: [email protected]
https://www.optimainsights.org
0 notes
Link
Migraine is painful headaches which are basic for an irregularly incapacitating neurovascular disorder that distresses younger adults, especially women due to regular changes in hormones. They can be preceded or accompanied by sensory warning signs and additional symptoms. The therapeutics can be either preventive or failed, caters to the treatment of acute or chronic migraine where the headache frequency and severity can be successfully controlled.
https://www.optimainsights.org/press-releases/11-migraine-drugs-market
1 note
·
View note
Text
Global sleep apnea devices market was valued at US$ 5.1 bn in 2018 and is anticipated to grow at a CAGR of 7.1% during the forecast period.
The Sleep Apnea Devices Market reached US$5.1 billion at the end of 2018 and is set to stride over US$8.83 Billion at the end of 2026, with a CAGR of 7.1%.
With more than one billion people suffering from sleep apnea, it has become one of the major disorders in recent times. Sleep Apnea is a potential sleep disorder characterized by the repeated intermittent block of breathing during sleep for a few seconds. Three types of sleep apnea are reported namely obstructive, central and mixed. Of which, Obstructive Sleep Apnea (OSA) is the common type resulting from airway obstruction due to which the breathing is blocked for at least ten seconds.
In 2007, the World Health Organization (WHO) estimated the OSA to be over 100 million, but the numbers have significantly increased in recent times. In the US, sleep apnea is considered one of the major disorders where the average sleeping hours during night time is not more than 6 hours. Approximately 22.5% of women and more than 45% of men suffer from sleep apnea problems wherein 1 in 12 individuals report for obstructive sleep apnea. The prevalence of OSA occurs in about 26% of the adult population between 30 and 65 years and around 2-4% of the children aged 2-8 years. OSA also increases the occurrence of cardiac co-morbidities including heart failure by more than 100%, stroke by more than 50% and CAD by more than 25%. Also, there are high chances of developing psychological comorbidities such as anxiety, depression, bipolar disorders, etc.
With increase in the geriatric population prevalent with sleep apnea, diseases which can lead to development of Sleep Apnea such as stroke, hypertension, diabetes, obesity, stress, etc., rising awareness among the patients, development of healthcare infrastructure for advanced treatment methodologies, is set to drive the Sleep Apnea Market in the forthcoming years. Yet, patient discomfort while using sleep apnea devices and the competitiveness of the market comprising of several advanced devices can hamper the market growth.
The Sleep Apnea diagnosis market is growing along with the treatment market which comprises of actigraphs, pulse oximeters, respiratory polygraphs, polysomnography, etc. The polysomnography devices occupied a market share of more than 34% in the year 2018 and are said to contribute to growth with a CAGR of around 6.78% during the forecast period. This is because, polysomnography is one of the most trusted and preferred methodologies for detecting sleep apnea, especially the apnea-hypopnea index (AHI). Besides, the respiratory polygraph devices market is set to expand at a CAGR of 7.2% where these devices are primarily used in the screening of sleep apnea in homes similar to polysomnography used in clinics and hospitals. Respiratory polygraph is one of the preferred methods by patients due to its cost-effectiveness. This is set to drive the overall sleep apnea diagnostic market to grow at a CAGR of 6.49% between 2019 and 2026.
Positive Airways Pressure (PAP) devices are the standard treatment availed by many people worldwide. These devices are mainly prescribed for OSA but can be used for central sleep apnea treatment as well. The device pushes air through the nasal routes through the airway passage at a high pressure preventing the occurrence of apnea during sleep. This enables normal sleep for individuals suffering from sleep apnea and also reduces the risks of developing comorbidities associated with sleep apnea. In recent times, sleep apnea devices are miniaturized to make it comfortable for patients to carry wherever they travel. This level of advancement is promoting sleep apnea devices for treatment and is also propelling market growth.
The North American region ruled the market with over 50% of the market share followed by the European market with around 35% with Asia-Pacific and LAMEA contributing to nearly 12% of the total market share. The tremendous growth in the North American region can be attributed to technological advancement which is enabling the researchers to conduct more sleep tests to identify and diagnose the patients suffering from sleep apnea. Also, the awareness among the population regarding the sleep apnea had surged leaps and bounds. In the European market, especially Germany and France are said to contribute more towards the market growth as the awareness among people regarding the treatment available is more. Further, the reimbursement policies are also aiding market growth in the region.
In the Asia-Pacific region, the market remains mostly untapped as a greater number of individuals suffering from the condition remain undiagnosed and unaware of the condition. Lack of awareness and lack of technological development are also the reason why this market is still in its nascent stages. However, the penetration of companies across the Asian market is eventful in recent periods which is becoming a lucrative region for investment. Also, government policies support the manufacturing and pharma companies to strengthen their presence. The growing population, increase in the number of clinics, rising health care expenditure, etc. expected to contribute to robust growth in the Asia-Pacific region in the forecast period between 2019-2026.
The Sleep Apnea market is segmented based on therapies, product types, regions, end-user, and epidemiology. The Sleep Apnea Devices Market Outlook 2019-2026, from Optima Insights, will offer a thorough insight on the market growth till the forecast year 2026 based on the market segmentation (Epidemiology, Therapies, Disorder Type, End-user and Region). The report comprises comprehensive profiling of companies involved in treatment devices and products under development for sleep apnea.
There are 17 Key Major Players including Philips Respironics, Resmed, Medtronic, Resonea, Apex Medical, Itamar Medical Ltd., Respicardia, Inc, Invacare Corporation and many more. Also, 14 companies are classified under the category of New Market Entrants and Emerging Companies. With stringent regulations for sleep apnea devices manufacturing, the new barrier has risen for the companies for increasing their geographical presence and also handle the competition within the market.
Key Developments
June 2019: The study published in CHEST Journal suggests that CPAP-treated sleep apnea may be linked to a reduction in the risk of diabetes
June 2019: Israeli’s Itamar Medical's FDA-cleared WatchPAT, to integrate sleep apnea management into the cardiac patient care pathway
June 2019: Signifier Medical Technologies closes Series 2 funding round for continued development of daytime neurostimulator for snoring, mild sleep apnea
The Report Provides Key Insights on
· History of the Sleep Apnea Devices Market, 2015 to 2017
· Forecast of the Sleep Apnea Devices Market Growth till the year 2026
· The key market drivers, restraints, challenges, future opportunities and the market dynamics driving the Sleep Apnea Devices Market
· Analysis of potential growth segments which will drive the market
· Landscape analysis of the major companies, and new market entrants and companies which possess disruptive technologies which can change the trend of the entire market
· Key market approaches adopted by the organizations and in-depth intelligence of potential strategies which could alter the market dynamics
Sleep Apnea Devices Market Based on Epidemiological Assessment (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)
· Adherence Assessment
· Prescription Pattern Assessment
· Epidemiological Assessment
Sleep Apnea Devices Market Based on Alternate Therapies (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)
· Positional Therapy
· Oral Pressure Therapy
· Hypoglossal Nerve Stimulation
· Expiratory Positive Airway Pressure
Sleep Apnea Devices Market Based on Type (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)
· Diagnostic Devices
· Sleep Screening Devices
· Oximeters
· Actigraphy Systems
· Home Sleep Testing Devices
· Polysomnography Devices
· Therapeutic Devices
Sleep Apnea Devices Market Based on End-User (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)
· Home Care Settings
· Sleep Laboratories & Hospitals
Sleep Apnea Devices Market Based on Geographic Region (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)
· North America
· Europe
· APAC
· LAMEA
Sleep Apnea Devices Market Competitive Analysis (Company Overview, SWOT Matrix, Financial, Product Overview, and Market Strategies)
· Natus Medical Incorporated
· Nihon Kohden Corporation
· Fisher & Paykel Healthcare Limited
· Apex Medical
· Invacare Corporation
· Philips Respironics
· Respicardia, Inc.
· Vyaire Medical
About Us
Optima Insights is an innovative research and insights-driven enterprise committed to offering actionable intelligence to the global life science and healthcare market. We believe that meaningful insights and improved strategic content hold the key to improved ROI for our clients. We strike an innovative engagement model with our clients to Co-Create Intelligence that would address very specific issues facing them within their functional areas. We continuously support clients through the entire journey map to enable them to make better business decisions towards attaining market leadership.
Contact
Optima Insights
Chaucks G
+91 966 6620 365 (Asia) | +1 424 2554 365 (US)
Email: [email protected]
https://www.optimainsights.org
0 notes
Text
Research Antibody Production Market Expected to Expand at a Steady CAGR through 2018 – 2026
Antibody Production Market was valued at US$9.93 billion in the year 2018 and is expected to reach US$23.22 billion by 2026, at a CAGR of 12.29%.
Antibodies are protein molecules resembling the alphabet ‘Y’. They are innately produced by plasma cells as a primary response and also produced by B cells. They are a part of the immune system that protects against toxins, antigens, and pathogens such as bacteria and viruses. When an antigen or an organism enters the body, the macrophages present them to B cells. The B cells codes for a new antibody containing an antigen-binding site that is specific to the epitope of the antigen. The antibodies are then released to the bloodstream and B cells produce the same type of antibodies if they encounter with the same antigen once again.
The spotlight on antibodies arose due to its high specificity towards the targeted cells while sparing the normal cells. The antibodies can be custom-made against a particular epitope through hybridoma technology. The antibodies which target one epitope are monoclonal antibodies (mAbs) whereas antibodies targeting multiple epitopes are denoted as polyclonal antibodies. The ability to produce antibodies by connecting to specific antigens is used in manufacturing probes that have the capability of identifying specific molecules and can be used across a spectrum of research and diagnostic purposes.
With more inclination towards targeted antibody therapy, and with biotechnology and biopharmaceutical companies focusing more on antibody production for specific requirements, the market is set to grow at a CAGR of 12.29% during the forecast period.
Rising geriatric population around the world, increase in the prevalence of infectious and disorders such as cancer, rheumatoid arthritis, and other chronic diseases, more and more interest towards targeted therapy are driving the antibody production market. Also, there is a steep surge in the antibody production due to an increase of biotechnology and biopharmaceutical organizations investing more funds in research and development owing to develop advanced biologics and therapeutics with a principal focus on monoclonal antibodies. However, an increase in the number of local players, cost of the therapy and failure during approvals are the factors which may likely hamper the market growth.
More than 650 companies are present in the field of antibody production and more and more therapeutic uses are being discovered. The long-term strategy for market sustenance and attaining leadership in the sector will happen through partnerships and collaborations. Further, patent expiry on several blockbuster mAbs is yet another factor that will support the antibody production market. For example, Herceptin patent expired in Europe in the year 2014 and its US patent expired in June. Following the expiration of Samsung epis patent, Mylan and Biocon have already obtained FDA approval for Herceptin Biosimilar. Companies such as Amgen, Allergan, Pfizer, etc., are also keen on launching their biosimilar depending upon the competition, pricing of the competitors, etc.
The antibody production market is categorized based on the type of antibodies, production process, end-use, and regions.
The monoclonal antibody (mAbs) segment engrossed maximum revenue when compared to the polyclonal antibody segment, in the year 2016-17 and is set to capture the market in the forecast period. This is due to the upsurge of investments in mAb research and more interests towards targeted therapeutic approaches, the launch of new products, etc. However, the polyclonal antibody segment will also contribute owing to its increasing popularity, production cost, etc. reaching over US$ 1 billion by 2024. The antibodies used for research purposes will contribute more towards the market growth, than the contribution of polyclonal antibodies.
Generally, bioreactors are utilized for large-scale production of antibodies. Following which they are clarified using the downstream methodology which involves sophisticated, precise and effective procedure including filtration, chromatography, resins, etc. The downstream processing segment chiefly contributes to the antibody production market.
Owing to the production of antibodies with superior product quality and production of novel therapeutic antibodies, the filtration and upstream processing segment will play a crucial role in the forthcoming years and will significantly contribute to the market growth.
The pharmaceutical and the biotechnology companies are said to dominate the overall market share with maximum revenue generation in the years 2016 to 2018. With more new market entrants, products in the pipeline, major players planning to expand their product portfolio, more investments in therapeutic development, the pharma and biotech companies will lead the market growth by a significant margin.
Especially in the continent of North America, where the conditions for R&D are very favorable and increasing advancement for treating chronic disorders promptly puts it ahead in the revenue generation over other regions. However, awareness of treatment for chronic disorders in the Asia Pacific regions will slowly grow towards the end of 2021, especially in countries such as India and China, where the scope of investment for developing therapeutics is huge due to its diversity in the genomic pool, lack of stringent regulations, continual improvement in healthcare infrastructure, etc.
Companies such as GE Healthcare, Thermo Fisher Scientific, Inc., Pall Corporation, INTEGRA Biosciences AG, Eppendorf AG, Danaher Corporation, Abcam plc, etc. all focus on both upstream and downstream segments.
The Antibody Production Market Outlook 2019-2026, from Optima Insights, will offer a thorough insight on the market growth till the forecast year 2026 based on the market segmentation (Type, Process, End-Use, and Region). The report also comprises comprehensive profiling of companies involved in antibody production, product information and pipeline information.
The Report Provides Key Insights on
· History of the Antibody Production Market, 2015 to 2017
·
· Forecast of the Antibody Production Market Growth till the year 2026
· The key market drivers, restraints, challenges, future opportunities and the market dynamics driving the Antibody Production Market
· Analysis of potential growth segments which will drive the market
· Landscape analysis of the major companies, and new market entrants and companies which possess disruptive technologies which can change the trend of the entire market
· Key market approaches adopted by the organizations and in-depth intelligence of potential strategies which could alter the market dynamics
Antibody Production Market Based on Process (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)
· Upstream Processing
· Consumables
· Reagents and Buffers
· Media
· Bioreactors
· Single-Use Bioreactors (SUBS)
· Large-Scale Bioreactors
· Filtration
· Filtration Systems
· Consumables & Accessories
· Purification Process
· Chromatography Resins
· Chromatography Systems
Antibody Production Market Based on Type (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)
· Monoclonal Antibody
· Humanized
· Chimeric
· Murine
· Polyclonal Antibody
Antibody Production Market Based on End-User (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)
· Research Laboratories
· Pharmaceutical Companies
· Biotechnology Companies
Antibody Production Market Based on Geographic Region (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)
· North America
· Europe
· APAC
· LAMEA
Antibody Production Market Competitive Analysis (Company Overview, SWOT Matrix, Financial, Product Overview, and Market Strategies)
· Thermo Fisher Scientific, Inc.
· Sartorius AG
· Merck KGaA
· Pall Corporation
· Eppendorf AG
· Danaher Corporation
· Miltenyi Biotec
· Bio-Rad Laboratories Inc
About Us
Optima Insights is an innovative research and insights-driven enterprise committed to offering actionable intelligence to the global life science and healthcare market. We believe that meaningful insights and improved strategic content hold the key to improved ROI for our clients. We strike an innovative engagement model with our clients to Co-Create Intelligence that would address very specific issues facing them within their functional areas. We continuously support clients through the entire journey map to enable them to make better business decisions towards attaining market leadership.
Contact
Optima Insights
Mr Chucks G
+91 966 6620 365 (Asia) | +1 424 2554 365 (US)
Email:[email protected]
https://www.optimainsights.org
1 note
·
View note